GENSCRIPT BIO's stock price surged 5.08% during intraday trading on Tuesday, marking a significant upward movement for the biotechnology company.

The movement appears linked to the market's assessment of the company's recently reported full-year 2025 financial results and its strategic expansion. While the company swung to a reported net loss of US$532.83 million from a prior-year profit, this was primarily due to the absence of a large one-time unrealised gain from deconsolidation recorded in 2024. Investors may be focusing on the underlying operational performance, which saw sales rise to US$959.53 million.

Further optimism is likely driven by the company's ongoing investment in its high-growth platforms, particularly its mRNA capabilities. The recent opening of its Delft mRNA manufacturing facility in the Netherlands embeds the company in a major European life sciences hub. Analyst projections included in related coverage suggest significant future revenue and earnings growth by 2028, alongside a fair value estimate representing substantial upside potential from current price levels.